KarX-EC

KarX-EC is an enteric-coated xanomeline capsule being developed by Bristol Myers Squibb as an add-on to KarXT (xanomeline/trospium, marketed as Cobenfy) for agitation in Alzheimer's disease. Five concurrent Phase 3 trials are enrolling across AD agitation (ADAGIO-1, ADAGIO-3, NCT07011745), AD cognitive impairment (MINDSET 2), and an adolescent long-term safety study in schizophrenia and autism-related irritability (NCT07424404) [2][3][4][5][6]. Total program enrollment runs to roughly 2,500 patients across the five trials. BMS paid roughly $14 billion for Karuna in 2024 [11], so expanding beyond adult schizophrenia is central to the deal thesis, especially given Cobenfy's muted launch trajectory (Q1 2026 net sales of $56 million and Q2 2026 of $63 million against pre-launch bull-case models [7][12]).

Xanomeline/trospium (Cobenfy) is already FDA-approved for adults with schizophrenia as of September 2024, the first mechanistically new antipsychotic in decades [1]. KarX-EC itself is a new formulation layered on top of that base regimen: an enteric-coated capsule of xanomeline alone (BMS-986519), designed to deliver more xanomeline past the stomach so dose can be pushed higher without the gastrointestinal side effects that have dogged the molecule since the 1990s. The AD program is first-in-class for muscarinic agonism in this indication, though the underlying M1/M4 target is clinically validated via Cobenfy's schizophrenia approval. BMS is running five Phase 3 trials in parallel for AD agitation (ADAGIO-1, NCT07011745, long-term safety in ADAGIO-3), AD cognitive impairment (MINDSET 2), and adolescent psychiatric indications (NCT07424404 covers schizophrenia and autism-related irritability in adolescents) [2][3][4][5][6]. No breakthrough, fast track, or priority review designations have been publicly disclosed for the AD indications. Given 14-week primary endpoints and recruitment that began in 2025 and 2026, first Phase 3 agitation readouts are plausible in 2027. The BMS Q2 2026 10-Q discussed Cobenfy launch dynamics and reported quarterly Cobenfy net sales of $63 million but did not provide specific guidance on AD readout timing [7][12].

Muscarinic receptors are a family of acetylcholine receptors scattered through the brain and body. Two subtypes, M1 and M4, cluster in brain regions that govern cognition, mood, and dopamine signaling. Activating M4 dampens the hyperactive dopamine release behind psychosis and agitation. Activating M1 can sharpen cognitive processing. Think of them as volume dials on circuits that go haywire in schizophrenia and Alzheimer's. Xanomeline is a brain-penetrant M1/M4 agonist. The clever part of KarXT is pairing xanomeline with trospium, a muscarinic antagonist that cannot cross the blood-brain barrier. Trospium mops up xanomeline's effects on muscarinic receptors in the gut and salivary glands (nausea, sweating, diarrhea, syncope) without touching the brain targets. Those peripheral side effects killed xanomeline's original development program in the late 1990s. The validation case is stronger than most first-in-class CNS stories: a 1997 xanomeline monotherapy trial in Alzheimer's actually showed cognitive and behavioral improvements before the GI tolerability problem forced abandonment [8]. The EMERGENT-2 and EMERGENT-3 schizophrenia trials later confirmed the mechanism works clinically when the peripheral side effects are blocked [9]. KarX-EC extends this strategy by delaying xanomeline absorption until past the stomach, which should let patients tolerate higher brain exposure. Translating that pharmacology benefit into measurable efficacy gains in older AD patients is what the Phase 3 program has to prove.

BMS is running five Phase 3 trials with a combined program enrollment of roughly 2,500 patients. ADAGIO-1 (NCT07011732) and NCT07011745 are 14-week randomized placebo-controlled trials, each targeting 426 patients, with change from baseline on the CMAI-IPA total score at Week 14 as the primary endpoint [2][3]. CMAI-IPA (Cohen-Mansfield Agitation Inventory, International Psychogeriatric Association modified version) is a validated scale clinicians use to score the frequency and severity of agitation behaviors in dementia patients. ADAGIO-3 (NCT06937229) is a long-term open-label safety and efficacy study, n=650, with TEAEs (treatment-emergent adverse events, meaning any side effect that appears or worsens after treatment starts) as the primary endpoint [4]. MINDSET 2 (NCT06976203) tests the KarXT plus KarX-EC combination for cognitive impairment in Alzheimer's using ADAS-Cog11 as the primary endpoint (a standard 11-item test of memory, orientation, language, and praxis that has been the workhorse cognitive outcome measure in AD trials for three decades), n=586 [5]. NCT07424404 is a long-term safety study of KarXT/KarX-EC in adolescents with schizophrenia and autism-related irritability, extending the Cobenfy franchise into pediatric psychiatry where off-label antipsychotic use is heavy and labeled options are limited [6]. The 14-week agitation design is standard for AD neuropsychiatric symptom trials: the Rexulti (brexpiprazole) development program used a CMAI-based framework and secured FDA approval for AD agitation in May 2023 [10]. Important caveat: the Rexulti pivotal trials used the standard CMAI, while ADAGIO uses CMAI-IPA, which is a different instrument with different anchors and scoring characteristics. Comparing effect sizes between the two programs requires instrument-specific benchmarks, not a direct number-for-number read-across. Running two identically designed placebo-controlled trials in parallel (ADAGIO-1 and NCT07011745) is likely intended to generate two positive studies in a single filing package. Recruitment is active across all five trials with no publicly flagged delays. The main design question is whether placebo response in nursing home and caregiver settings can be controlled tightly enough to detect a drug effect over 14 weeks.

Our model estimates a 54% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 51%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by a non-randomized design, more secondary endpoints than usual, and its light or open-label blinding; it is held back by weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is the dominant failure mode. AD agitation placebo arms are notoriously noisy because caregivers, routine changes, and nursing home interventions all drive non-specific improvements. If placebo-adjusted CMAI-IPA delta comes in small (the exact threshold depends on the instrument's effect-size characteristics, which differ from standard CMAI used in Rexulti trials), approval becomes much harder regardless of statistical significance. Dose risk is next: KarX-EC adds xanomeline on top of KarXT, and the window between therapeutic brain exposure and the historical GI and syncope problems is narrow. Trospium blunts peripheral effects but does not eliminate them entirely, and the public domain contains no Phase 2 dose-finding readout for the KarX-EC + KarXT add-on combination specifically. Safety risk centers on the elderly AD population, which is more fragile than the schizophrenia cohort where KarXT was approved. Orthostatic hypotension, syncope, and vomiting have shown up consistently in KarXT trials, and the FDA label for Cobenfy carries warnings for urinary retention, biliary disease, and hepatic injury [1]. Any cardiovascular signal in frail older patients would be a hard problem. Execution risk is non-trivial: five concurrent Phase 3 trials in overlapping AD populations will compete for sites and patients against Leqembi, donanemab, and the growing Rexulti real-world rollout. Commercial risk is real even on approval. Brexpiprazole is already on the market for AD agitation. Cobenfy's U.S. list price for schizophrenia is roughly $1,850 per month (about $22,500 annually) [13]; BMS will almost certainly carry that price point or higher into AD agitation, where payers and nursing-home formularies scrutinize geriatric antipsychotic spend tightly against generic quetiapine and risperidone. KarXT plus KarX-EC will need a differentiated tolerability profile (no tardive dyskinesia, minimal weight gain) and a clearly superior efficacy readout on CMAI-IPA to justify premium pricing in that setting.

Worth watching closely. BMS paid roughly $14 billion for Karuna [11], and Cobenfy's schizophrenia launch has been materially slower than pre-launch bull-case models: BMS reported Cobenfy net sales of $56 million in Q1 2026 and $63 million in Q2 2026, with multiple analyst notes characterizing the ramp as disappointing against initial peak-sales expectations in the multi-billion-dollar range [7][12]. AD agitation is the first expansion indication that could reshape the deal economics: the addressable market is in the $3 to 5 billion range depending on how physicians weigh KarXT against brexpiprazole and off-label antipsychotics. Patent runway supports the thesis: the base KarXT combination patents are expected to expire around 2030, while the Cobenfy bead-formulation patents extend to roughly 2039 (both before any Patent Term Extension) [14]. The signal to watch is the first ADAGIO Phase 3 topline, plausibly in 2027 given current recruitment. A clean CMAI-IPA hit with a tolerability edge over Rexulti would meaningfully re-rate the Karuna acquisition thesis. A miss would damage it. The lower-probability upside bet is MINDSET 2, which tests ADAS-Cog11 for cognitive impairment: any clean cognitive signal would substantially increase the long-term valuation given that no small-molecule cognitive therapies currently exist. Next check-in points: BMS Q4 2026 earnings for guidance on readout timing and Cobenfy ramp trajectory, any dose-finding or interim safety disclosures from ADAGIO-3, and any public update on Cobenfy's U.S. launch trajectory as a proxy for commercial pull in the broader franchise.